Clinical trials: Large B Cell Diffuse Lymphoma
Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
This investigator-initiated, single-center, single-arm, open-label Phase II study will evaluate the efficacy and safety of sonrotoclax in combination with glofitamab, gemcitabine, and oxaliplatin in adults with relapsed or…
- Trial name
- NCT07774234
- Testing
- Sonrotoclax, Glofitamab, Gemcitabine (1000 mg/m2)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, B-Cell, Relapsed Cancer
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.
- Conditions
- Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06004167
- Testing
- Adaptive Bridging Radiation Therapy (ABRT)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004858
- Testing
- B43-genistein immunoconjugate
- Where
- 3 sites in United States
- Sponsor
- Parker Hughes Cancer Center
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Diffuse Large B-Cell Lymphoma
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy…
- Trial name
- KPT-330+RICE (NCT02471911)
- Testing
- KPT-330, Rituximab, Etoposide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Weill Medical College of Cornell University
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding…
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03479268
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Lymphoma
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients…
- Trial name
- NCT00052442
- Testing
- pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
DLBCL - Diffuse Large B Cell Lymphoma
FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
The FERTILE study is a retrospective cohort study evaluating fertility after intensive treatment with RCHOP14/RCHOP21 or ACVBP in young patients with diffuse large B-cell lymphoma treated in clinical trials conducted by the LYSA…
- Trial name
- FERTILE (NCT06592846)
- Where
- 27 sites in France
- Volunteers
- 80 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B-cell-lymphoma
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix)…
- Trial name
- MATRix (NCT02531841)
- Testing
- Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®), Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
- Where
- 2 sites in Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Freiburg
Diffuse, Large B-Cell, Lymphoma
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
The use of R-CHOP, given every two weeks, will be associated with improvements in response rate, and progression-free survival, when compared to R-CHOP given every three weeks.
- Trial name
- NCT00599170
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Southern California
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05432635
- Testing
- Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous Hematopoietic Stem Cell Transplantation, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-Cell Lymphoma
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
This is a prospective, multicenter, single-arm clinical study designed to evaluate the efficacy and safety of Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage therapy for…
- Trial name
- NCT07001540
- Testing
- Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx)
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Diffuse Large B Cell Lymphoma Refractory
Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas
This is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large…
- Trial name
- GLO-PACT (NCT07387848)
- Testing
- Glofitamab
- Where
- Lebanon
- Volunteers
- 40 people
- Sponsor
- American University of Beirut Medical Center
DLBCL - Diffuse Large B Cell Lymphoma
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
Study designobservational, non-interventional, retrospective, multicenter study.
- Trial name
- POSS (NCT06734078)
- Where
- 9 sites in Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
This single-arm, prospective clinical study will evaluate the efficacy and safety of Zanubrutinib-based maintenance therapy for post-remission in newly diagnosed DLBCL who are intolerant to first-line intensive chemotherapy.
- Trial name
- NCT06669143
- Testing
- Zanubrutinib, Lenalidomide
- Volunteers
- 19 people
- Sponsor
- Ruijin Hospital
Lymphoma
S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00006708
- Testing
- filgrastim, rituximab, carboplatin
- Where
- 85 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00290706
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.